170 related articles for article (PubMed ID: 11108066)
21. Plasma oxypurinol as a measure of adherence in clinical trials.
Stamp LK; Merriman T; Frampton C; Zhang M; Wallace M; Miner JN; Dalbeth N
Ann Rheum Dis; 2018 Feb; 77(2):313-314. PubMed ID: 28057666
[No Abstract] [Full Text] [Related]
22. Relation between adverse events associated with allopurinol and renal function in patients with gout.
Vázquez-Mellado J; Morales EM; Pacheco-Tena C; Burgos-Vargas R
Ann Rheum Dis; 2001 Oct; 60(10):981-3. PubMed ID: 11557658
[TBL] [Abstract][Full Text] [Related]
23. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
[TBL] [Abstract][Full Text] [Related]
24. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.
Graham GG; Kannangara DR; Stocker SL; Portek I; Pile KD; Indraratna PL; Datta I; Williams KM; Day RO
Br J Clin Pharmacol; 2013 Dec; 76(6):932-8. PubMed ID: 23590252
[TBL] [Abstract][Full Text] [Related]
25. Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy.
Chung Y; Stocker SL; Graham GG; Day RO
Am J Med Sci; 2008 Mar; 335(3):219-26. PubMed ID: 18344696
[TBL] [Abstract][Full Text] [Related]
26. Allopurinol and kidney function: An update.
Stamp LK; Chapman PT; Palmer SC
Joint Bone Spine; 2016 Jan; 83(1):19-24. PubMed ID: 26453097
[TBL] [Abstract][Full Text] [Related]
27. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
[TBL] [Abstract][Full Text] [Related]
28. Up-titration of allopurinol in patients with gout.
Jennings CG; Mackenzie IS; Flynn R; Ford I; Nuki G; De Caterina R; Riches PL; Ralston SH; MacDonald TM;
Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169
[TBL] [Abstract][Full Text] [Related]
29. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Chao J; Terkeltaub R
Curr Rheumatol Rep; 2009 Apr; 11(2):135-40. PubMed ID: 19296886
[TBL] [Abstract][Full Text] [Related]
30. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
31. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
Roberts RL; Wallace MC; Phipps-Green AJ; Topless R; Drake JM; Tan P; Dalbeth N; Merriman TR; Stamp LK
Pharmacogenomics J; 2017 Mar; 17(2):201-203. PubMed ID: 26810134
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
[TBL] [Abstract][Full Text] [Related]
33. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
34. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
35. Plasma oxipurinol concentrations during allopurinol therapy.
Emmerson BT; Gordon RB; Cross M; Thomson DB
Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
[TBL] [Abstract][Full Text] [Related]
36. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
Day RO; Miners JO; Birkett DJ; Whitehead A; Naidoo D; Hayes J; Savdie E
Br J Clin Pharmacol; 1988 Oct; 26(4):423-8. PubMed ID: 3190992
[TBL] [Abstract][Full Text] [Related]
37. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
38. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
J Rheumatol; 2001 Oct; 28(10):2294-7. PubMed ID: 11669172
[TBL] [Abstract][Full Text] [Related]
39. More allopurinol is needed to get gout patients < 0.36 mmol/l: a gout audit in the form of a before-after trial.
Arroll B; Bennett M; Dalbeth N; Hettiarachchi D; Ben C; Shelling G
J Prim Health Care; 2009 Dec; 1(4):315-8. PubMed ID: 20690341
[TBL] [Abstract][Full Text] [Related]
40. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
